TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens

Yuichi Hikichi, Erik Kupperman|Molecular Cancer Therapeutics|2011

Cited by 77